IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Minieye Tec 02431.HK	Application Software	17-20.2	200	4,081	2024/12/20	Data is not available	2024/12/27
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	2024/12/27	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	2024/12/27	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	2024/12/27	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Minieye Tec
02431.HK

Application Software

17-20.2

200

4,081

2024/12/20

Data is not available

2024/12/27

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

2024/12/27

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

2024/12/27

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

2024/12/27

2024/12/30

Summary

We are a clinical-stage biopharmaceutical company committed to the discovery, acquisition, development and commercialization of differentiated targeted therapies to address unmet medical needs in cancer treatment. Since our inception in 2017, we have built a pipeline with 11 drug candidates, including Core Product TY-9591, six clinical stage products, and four preclinical stage products. We are currently conducting a pivotal Phase II clinical trial of TY-9591 monotherapy as first-line treatment of brain metastases from non-small cell lung cancer (“NSCLC”) with epidermal growth factor receptor (“EGFR”) mutations in China, as well as a registrational Phase III clinical trial of TY-9591 monotherapy as first-line treatment in locally advanced (stage IIIb or IV) or metastatic NSCLC with EGFR L858R mutation in China. THERE IS NO ASSURANCE THAT WE WILL ULTIMATELY BE ABLE TO DEVELOP AND MARKET OUR CORE PRODUCT OR ANY OF OUR PIPELINE PRODUCTS SUCCESSFULLY. Our Business Model Our core business model involves internally discovering, acquiring, developing, and commercializing small molecule drugs and other innovative drug species related to small molecule drugs to address unmet needs in cancer treatment, especially in lung cancer. We have developed in-house R&D capabilities that cover not only early-stage drug discovery, chemical synthesis and selection, but also clinical development and regulatory affairs. In addition, we have been actively seeking global and regional partnerships with leading pharmaceutical companies to maximize the clinical and commercial value of our drug candidates. As our Core Product TY-9591 enters pivotal clinical trial stage, we are in the process of establishing our in-house cGMP-compliant manufacturing facility in Huzhou, Zhejiang Province, which is expected to commence commercial-scale manufacturing by the end of 2025. We also plan to establish sales and marketing capabilities through a combination of in-house efforts and working with external partners to secure our success in commercializing this product in China. OUR DRUG CANDIDATES The field of cancer treatment has developed significantly in the past century. Conventionally, treatment methods such as surgery, radiotherapy, and chemotherapy have been widely utilized to fight against tumor cells, but they have been proven to be deficient due to side effects and limited efficacy. The development of targeted therapies, which target specific molecules, generally proteins, enzymes, a signaling pathway, or genetic changes that play a role in the spread of cancer, has embarked on a new era of cancer treatment with enhanced specificity and efficacy. For details on the history of cancer treatment development, see “Industry Overview — Major Indications.” Source: TYK Medicines-B (02410) Prospectus (IPO Date : 2024/08/12)
Listing Market	MAIN
Industry	Biotechnology - Pharmaceuticals
Background	H Shares
Major Business Area	N/A

Corporate Information

Substantial Shareholders	WU Yusheng & Associates (Total share: 35.39%); (H share: 23.85%) Jiangsu Addor Equity Investment Fund Management Co.,Ltd. (Total share: 5.50%); (H share: 10.59%) HE Chao & Associates (Total share: 5.23%); (H share: 3.53%) Changxing Xingchang Industrial Investment Partnership (Limited Partnership) (Total share: 4.58%); (H share: 8.83%)
Directors	WU Yusheng (Chairman and Chief Executive Officer and Executive Director) JIANG Mingyu (Vice President and Executive Director and Secretary to the Board) DING Zhao (Non-Executive Director) GU Eric Hong (Non-Executive Director) HE Chao (Non-Executive Director) LI Jun (Non-Executive Director) MENG Xiaoying (Non-Executive Director) LENG Yuting (Independent Non-Executive Director) SHEN Xiuhua (Independent Non-Executive Director) XU Wenqing (Independent Non-Executive Director) ZHANG Senquan (Independent Non-Executive Director)
Company Secretary	JIANG Mingyu WONG Wing Yee
Principal Bankers	China CITIC Bank Corporation Limited China Construction Bank
Solicitors	JunHe LLP O Melveny & Myers LLP
Auditors	Ernst & Young
Registered Office	Room 1901, 19th Floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.tykmedicines.com
Email Address	investors@tykmedicines.com
Tel No	(86 21) 6167-6766
Fax No	(86 21) 6010-7317

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates